Compare Icl Group Ltd (ICL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.47B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Icl Group Ltd is far larger — about 3× Recursion Pharmaceuticals Inc's market cap, and Icl Group Ltd pays a 4.11% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ICL | RXRX | |
|---|---|---|
Market Cap | $6.47B | $2.14B |
Volume | 1,387,140 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $6.79 |
52-Week Low | $4.80 | $2.84 |
Typical Hold Time | 56 Days | 22 Days |
Enterprise Value | $9.11B | $1.66B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no daily change, showing stable but muted short-term performance. The stock exhibits bearish technical signals with declining revenue and net income margins over recent years, though Q2 2026 earnings beat expectations. Analyst consensus is entirely neutral with 4 hold ratings and a $6.08 price target, suggesting limited near-term upside. Recent news highlights dividend stability and cost-transformation initiatives amid fertilizer industry headwinds.
ICL faces mixed prospects with stable cash flows and dividend payments offset by profitability pressures. The 19.7% upside to consensus target offers moderate potential, but investors must weigh declining margins against operational efficiency efforts. Key risks include input cost inflation and reduced fertilizer demand, requiring careful monitoring of Q3 2026 results and cost program execution.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
